electroCore,

electroCore, OCF Growth YoY

The Year-over-Year Operating Cash Flow Growth of electroCore, (ECOR) as of Oct 17, 2026 is -17.83 %. In the previous year, Year-over-Year Operating Cash Flow Growth was 52.63 % — a change of -133.88% (lower).

OCF Growth YoY

-17.83 %

YoY

-133.88%

Last updated:

Year-over-Year Operating Cash Flow Growth of electroCore, is 2025 -17.83 % . Year-over-Year Operating Cash Flow Growth of electroCore, was 2024 52.63 % . It decreases by -133.88% lower compared to the previous year.

The electroCore, OCF Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Growth YoY
Date
OCF Growth YoY
Jan 1, 2018
-85.99 USD
Jan 1, 2019
4.34 USD
Jan 1, 2020
55.51 USD
Jan 1, 2021
32.04 USD
Jan 1, 2022
-22.15 USD
Jan 1, 2023
11.88 USD
Jan 1, 2024
52.63 USD
Jan 1, 2025
-17.83 USD
The electroCore, OCF Growth YoY history
YEAROCF Growth YoYYoY
-17.83 %-133.88%
52.63 %+343.12%
11.88 %-153.63%
-22.15 %-169.13%
32.04 %-42.28%
55.51 %+1,179.49%
4.34 %-105.05%
-85.99 %-6.03%
-91.51 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

electroCore, Stock analysis

What does electroCore, do? electroCore, Inc. is a medical device company based in Basking Ridge, New Jersey, operating in the Health Care sector. The company focuses on non-invasive vagus nerve stimulation (nVNS) therapy, offering a hand-held device called gammaCore. This device provides non-drug treatment for adults experiencing episodic cluster and migraine pain. electroCore's technology targets primary headaches, including migraine and cluster headache, as well as related chronic conditions such as gastric motility disorders, psychiatric issues, sleep disorders, and pain disorders. The company went public via an IPO on June 22, 2018, and currently employs 83 full-time staff. Its headquarters are located in Basking Ridge, and it operates within the Health Care industry. electroCore's primary product, gammaCore, is designed for non-invasive cervical vagus nerve stimulation, aiming to address neurological, psychiatric, gastroenterological, and respiratory conditions. The company's website is https://www.electrocore.com/. electroCore is listed under the ticker ECOR with ISIN US28531P2020. The firm's commercial stage operations emphasize non-invasive therapeutic solutions without pharmaceutical intervention. electroCore, is one of the most popular companies on Eulerpool.

Frequently Asked Questions about electroCore, stock

Year-over-Year Operating Cash Flow Growth of electroCore, is -17.83 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Operating Cash Flow Growth electroCore, since 2006 – with annual values, charts, and detailed analysis.

OCF growth measures the percentage change in operating cash flow. Growing OCF indicates improving cash generation from core operations.

To evaluate Year-over-Year Operating Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Operating Cash Flow Growth.

Year-over-Year Operating Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Operating Cash Flow Growth's electroCore, historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — electroCore,

All Key Metrics — electroCore,